Standard Fixed Enoxaparin Dosing for Venous Thromboembolism Prophylaxis Leads to Low Peak Anti-Factor Xa Levels in Both Head and Neck and Breast Free Flap Patients.
Shoshana W AmbaniFuat Barış BengürLee J VarelasVu T NguyenCarolyn De La CruzTahsin Oguz AcarturkErnest K MandersMark W KubikShaum SridharanMichael L GimbelMario G SolariPublished in: Journal of reconstructive microsurgery (2022)
Standard fixed enoxaparin dosing for postoperative VTE prophylaxis does not achieve target afXa levels for the majority of our free flap patients. H&N patients appear to be a particularly high-risk group that may require a more personalized and aggressive approach. Total body weight is the sole negative predictor of afXa level, supporting a role for weight-based enoxaparin dosing.